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Abstract Two common mutations, 677 C→T and a1298
A→C, in the methylenetetrahydrofolate reductase gene
(MTHFR) reduce the activity of MTHFR and folate metabo-
lism. Familial aggregation in a variable but significant
proportion of gastric cancer (GC) cases suggests the impor-
tance of genetic predisposition in determining risk. In this
study, we evaluate MTHFR polymorphisms in 57patients with
a diagnosis of GC, in 37 with a history of GC in first-degree
relatives(GC-relatives),andin454blooddonors.Helicobacter
pylori (HP) infection was also determined. An increased risk
was found for 677TT in GC patients with respect to blood
donors (odds ratio (OR)=1.98), and statistical significance
was sustained when we compared sex–age-matched GC
patients and donors (OR=2.37). The 677TT genotype
association with GC was found in women (OR=3.10), while
a reduction in the 667C allele frequency was present in both
the sex. No statistically significant association was detected
when 677–1298 genotype was stratified by sex and age. Men
of GC-relatives showed a higher 1298C allele frequency than
donors (OR=4.38). Between GC and GC-relatives, HP
infection frequency was similar. In conclusion, overall
findings support the hypothesis that folate plays a role in
GC risk. GC-relatives evidence a similar 677TT frequency to
that found in the general population.
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Introduction
Although the incidence of gastric cancer (GC) decreases
worldwide, at present, it is still the fourth more frequent
tumor in the world [1]. There are however major geograph-
ical differences among different countries. Regions with a
high incidence include East Asia (China and Japan),
Eastern Europe, and parts of Central and South America.
Areas with a low incidence include Southern Asia, North
and East Africa, and North America [2]. Within the
European Union, the highest incidence rate is in Lithuania;
the lowest is in Denmark. In Italy, GC incidence of female
and male is 27.7 and 40.7 cases every 100,000 habitants,
respectively [3]. GC is usually diagnosed at an advanced
stage, with >50% of patients having stage 3 or 4 disease at
presentation. Advanced GC has a poor prognosis, with a
relative 5-year survival rate of 7–27% [4].
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DOI 10.1007/s13277-009-0004-1It is generally accepted that multiple factors play a role in
GC development, including diet, lifestyle, infectious agents
such as Helicobacter pylori, and genetic factors as well as
gene–environment interactions [2]. Although the continuous
decrease in the incidence of GC [5]i nr e c e n td e c a d e sc a nb e
explained by changing lifestyle, diet habits, and reduced H.
pylori infection, the fact that some individuals develop GC
while others do not under similar environmental exposures
suggests that genetic predisposition plays an important role
in the pathogenesis of this disease. Approximately 10–15%
of gastric cancers arise in individuals with a family history of
the condition, while the risk of GC increases in first-degree
relatives of patients with the disease by approximately two-
to threefold [6–8]. This may be partially due to the fact that
relatives tend to be exposed to the same environmental risk
factors, but also to inheritable susceptibility. In addition, a
more common coincidence of the disease in homozygotic
than in heterozygotic twins [9] also supports genetic links
with GC. Only a few studies have investigated the
association of family history with GC. No significant
associations emerged to sex or age, education, body mass
index, or tobacco smoking, while the odds ratio (OR) was
higher when the affected relative was a sibling rather than a
parent [10,11]. Lifestyle and diet may explain this finding,
since it is possible that patients shared lifestyle more with
sibling than with parents. Although the H. pylori infection,
the best-established risk factor for GC, tends to be more
frequently found among family members [12–14], it is still
controversial if the risk for GC is associated with H. pylori
status in these patients.
Methylenetetrahydrofolate reductase (MTHFR) is a key
enzymein the metabolismoffolate, whose roleinGC, though
not always consistent in various studies [15], has been
supported by several meta-analyses [16–19]. Folate deficien-
cy may cause uracil misincorporation and subsequent DNA
instability [20], retarded DNA repair capacity for oxidative
or alkylating damage [21], and favor global and oncogenic
DNA hypomethylation [22]; all effects that can be involved
in carcinogenesis, including the GC [23,24]. Folate is one of
the important constituents in fruit and vegetables, and
epidemiologic studies have shown that a small consumption
of vegetables and fruits is associated with increased risk of
GC [25–27]. In most studies, the 677TT variant genotype
was associated with an increased risk of GC [16–19].
Accordingly, individuals who are homozygous for this
variant have 30% of the expected “in vitro” enzyme activity
compared with those who are homozygous for the CC677,
whereas heterozygous carriers have a 65% enzyme activity
[28]. Patients with the second variant 1298CC have a less
essential reduced folate reductase activity of 60% compared
with subjects carrying the AA1298 wild-type genotype, and
80% for the heterozygotes. The 1298CC was generally not
associated with GC risk in Caucasian population, while the
same was found to be a controversial risk factor mainly in
East Asia [16,17]. In animal models, an intervention study
provided evidence on the chemopreventive effect of folic
acid on GC [29]; while epidemiological studies on humans
were not so conclusive. Evidence for a significant association
between dietary folate intake and risk of GC was inconsistent
in some studies [15,18], and supported in others [17,19].
The present study tries to give an insight in the role of
MTHFR polymorphism in the northeast Italian GC popula-
tion,andwithrespecttofamilyhistory.Toourknowledge,this
is the first study aiming at examining the frequency of
MTHFR genetic variations in association with a risk
population from first-degree GC family history.
Material and methods
Study population
Baseline characteristics of the study population were
reported in Table 1. Fifty-seven unrelated patients, with a
histologically confirmed GC (35 male and 22 female) age
37 years or more, were recruited into the study. All patients
had a Caucasian ethnic background and were resident in
northeast Italy. They underwent clinical examination at the
Centro di Riferimento Oncologico (Aviano, Italy) between
2003 and 2008. Their median age was 54.
Between 2004 and 2008, 37 individuals (21 male and 16
female), who reported an ascertained case of GC among first-
degree relatives (parents, children, siblings, and offsprings),
were consecutively recruited from the same center. Their
median age was 44 years. Fifteen familiar histories with more
than one individual participating in the study were illustrated
in Fig. 1, remaining GC cases were not illustrated since
represented by only one family member. All subjects
enrolled were volunteers. Neither cancer nor intestinal
metaplasia/dysplasia was evidenced in these subjects by
gastroscopy and histological examination.
The control group comprised 454 blood donors younger
than 66 years (311 male and 143 female), recruited from the
samecenter.Theirmedianagewas40years.Theadvancedage
of patients with GC (mean 54 years; minimum 37; maximum
84) reduced the number of recruited controls useful for the
case-control analysis. Each matched case-control included one
caseandtwocontrols,then,ninety-sixdonorswerematchedin
sex and age (±1 year) to 48 individuals with GC.
Blood sample collection and DNA extraction
A venous blood sample was drawn from each of the
participants. Our institution’s review board has approved
the study proposal according to the Declaration of Helsinki,
and a written informed consent was obtained from subjects.
24 Tumor Biol. (2010) 31:23–32Genomic DNAwas extracted using the QiaAmp DNA Mini
Kit (Qiagen, Valencia, California, USA). Genomic DNA in
solution was stored at 4°C.
MTHFR genotyping
Predesigned Taq Man® SNP genotyping assays were used
on ABI 7900HT (AB Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions for the dis-
crimination of the 677 C→T (rs1801133) and 1298 A→C
(rs1801131) polymorphisms. The Applera TaqMan Univer-
sal Master® mix was employed together with the validated
primers and probes mix at the usage concentration as
provided by the manufacturer. Positive controls were
included in the analyses.
H. pylori identification
Routine formalin-fixed and paraffin wax-embedded pairs of
antrum, corpus, and fundus biopsies from GC patients and
GC-relatives were investigated by histology. Sections were
stained with hematoxylin and eosin (H&E) and examined
under light microscope at ×40 magnifications. Bouin’s
solution is an excellent fixative for the identification of H.
pylori (HP) in H&E-stained sections.
Statistical analyses
Hardy–Weinberg equilibrium was assessed by χ
2 analysis.
For each groups, subjects were divided according to
MTHFR genotype. The odds ratio and 95% confidence
interval (95% CI) were calculated to estimate the relative
risk of GC associated with MTHFR genotype [30]. Graph-
Pad software (Inc, San Diego, CA) was used to perform
Fisher’s exact test to compare two categorical variables.
Results
We analyzed 677 and 1,298 variants in a series of 454 blood
donors, 57 GC, and 37 GC-relatives recruited at the same
center;allwereofaCaucasianethnicbackgroundandresident
in northeast Italy. Among blood donors, two consecutive sex-
and age-matched individuals every one case of GC were
selected(n=96 matched controls for 48 GC). The description
of the study populations and of the observed MTHFR
polymorphisms was reported in Tables 1, 2,a n d3,
respectively. In patients with GC, distribution of 677TT
genotype showed a significant difference from controls
(24.56% vs 14.10%, OR=1.98, 95%CI: 1.037 to 3.833),
while they did not statistically differ in the 1298CC (Tables 2
and 3). The unfavorable 677TT variant showed also an
increased frequency in GC samples (27.08%) with respect to
age- and sex-matched controls (13.54%, OR=2.37; 95%CI:
0.999 to 5.628; Tables 2 and 3). The difference is associated
with a higher homozygous 677TT variant in women (OR=
3.10; 95%CI: 1.052 to 9.135, Table 2)t oc o m p a r e dw i t h
women control group, and with a lower 667C wild-type
allele frequency in GC of both sex with respect to controls
(Table 3). Table 4 details the distribution of 677–1298
genotype polymorphisms and sex and age. Odd ratio analysis
was obtained by comparison with a reference group of
Table 1 Baseline characteristics of the study population
Numbers Mean of age at diagnosis/selection (minimum–maximum)
Controls 454 40 (18–66)
Sex- and age-matched controls 96 49 (37–64)
Men 315 (68.50%) 40 (19–65)
Women 139 (31.50%) 38 (18–66)
<54 years 411 (90.53%) 36 (18–53)
≥54 years 43 (09.47%) 58 (54–66)
GC cases 57 54 (37–84)
Sex- and age-matched GC 48 48 (37–64)
Men 35 (61.40%) 55 (39–84)
Women 22 (38.60%) 52 (37–75)
<54 years 29 (50.88%) 46 (37–53)
≥54 years 28 (49.12%) 62 (54–84)
GC-relatives cases 37 44 (25–74)
Men 21 (56.76%) 47 (25–74)
Women 16 (43.24%) 41 (31–60)
<54 years 29 (78.38%) 39 (25–49)
≥54 years 8 (21.62%) 64 (57–74)
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26 Tumor Biol. (2010) 31:23–32individuals carrying the two wild-type 677CC and 1298AA
alleles. Data for men showed a trend to an increased
frequency of both MTHFR 677 and 1298 variant genotypes
in GC cases, while women showed a possible GC risk
reduction associated with the homozygous variant MTHFR
1298CC genotype. The association of MTHFR variant
association also seems to be influenced by the age of
patients (age ≥54). However, none of the above reported
differences reach any statistical significance in our series.
Any samples showed genotype in homozygosis for both
the 677TT and 1298CC polymorphisms. By converse, GC-
relatives showed a similar 677TT genotype frequency
(13.5%) than control samples (14.1%); not even a statisti-
cally significant difference in 1298CC genotype frequencies
was found between the GC-relatives and controls (Tables 2
and 3). An increase in 1298 heterozygosis was found in GC-
relatives with respect to GC (Table 2). Stratification of 677–
1298 genotypes by sex and age was similar to that found in
GC cases to compare with donors; and also in this situation,
data did not reach any statistical significance (Table 5).
In Fig. 1, the 677 and 1298 allele distribution was
illustrated in 15 families with more than one subject
enrolled in the study for a total of 27 GC-relatives.
Additional ten GC-relatives, as single case, were not shown
in Fig. 1. Neither cancer nor intestinal metaplasia/dysplasia
was evidenced in these individuals by gastroscopy and
histological examination. Data from histological identifica-
tion of H. pylori were reported across family group in
Fig. 1. HP infection was frequently found within related
subjects. Hp infection frequencies in GC and GC-relative
groups and their relative distribution in 677 genotypes were
resumed in Fig. 2. There was no statistically significant
difference in Hp distribution among all the groups tested.
Discussion
The high mortality of GC is largely attributed to the huge
number of at-risk individuals as well as to the delay in
Table 2 Genotypic of the MTHFR 667 and 1298 polymorphisms in controls, GC patients, and GC-first grade relatives
Numbers 667 genotype 1298 genotype
CC CT TT AA AC CC
Controls 454 152 (33.5%) 238 (52.4%) 64 (14.1%) 179 (39.4%) 234 (51.5%) 41 (9.0%)
Sex- and age-matched controls 96 37 (38.6%) 46 (47.9%) 13 (13.5%) 33 (34.4%) 54 (56.2%) 9 (9.4%)
Men 315 100 166 49 133 158 24
Women 139 52 72 15 46 76 17
<54 years 411 139 215 57 161 211 39
≥54 years 43 13 23 7 18 23 2
GC cases 57 18 (31.6%) 25 (43.9%) 14 (24.6%)
a 25 (43.9%) 27 (47.4%) 5 (8.8%)
Sex- and age-matched GC 48 12 (25.0%) 23 (47.9%) 13 (27.1%)
b 24 (50.0%) 19 (39.6%) 5 (10.4%)
men 35 10 17 8 13 18 4
women 22 8 8 6
c 12 9 1
<54 years 29 7 16 6 15 11 3
≥54 years 28 11 9 8 10 16 2
GC-relatives cases 37 14 (37.8%) 18 (48.6%) 5 (13.5%) 9 (25.7%) 26 (70.3%)
d 2 (5.7%)
Men 21 8 11 2 3
e 17
f 1
Women 16 6 7 3 6 9 1
<54 years 29 12 13 4 7 20 2
≥54 years 8 2 5 1 2 6 0
aOR=1.98, 95% CI: 1.027 to 3.833, with respect to controls
bOR=2.37, 95% CI: 0.999 to 5.628, with respect to sex- and age-matched controls
cOR=3.10, 95% CI: 1.052 to 9.135, with respect to women controls
dOR=2.22, 95% CI: 1.072 to 4.605, with respect to controls
eOR=0.23, 95% CI: 0.066 to 0.790, with respect to men controls
fOR=4.22, 95% CI: 1.389 to 12.84, with respect to men controls
Fig. 1 The 677 and 1298 genotypes analysis and H. pylori infection
status of 15 pedigrees with at least one first-degree GC-affected
member. Figure illustrates 15 representative family histories with at
least one subject with a histological ascertained GC. Only subjects in
first-degree GC-relatives were included in the GC-family group for the
study. Ten cases were excluded from the figure, because the biopsies
from their first-degree GC relatives were not available

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tion of GC seem to be the most promising approaches in
reducing the incidence and mortality related to this cancer.
Some possible risk factors that can be avoided in GC-
relatives, i.e, smoking, alcohol consumption, dietary intake,
H. pylori infection, have widely been studied with the aim
of preventing GC. The risk of GC in family history was
found to be independent of tobacco smoking [10]. Large
alcohol consumption has been proved to contribute to GC,
to reduce folate intestinal absorption, and to increase folate
renal excretion [31,32]. According to a recent report from
the World Cancer Research Fund and the American
Institute for Cancer Research, there is a “probable evi-
dence” that large consumption of nonstarchy vegetables
and fruits might decrease the risk of GC, while salt and
salted food might be directly associated with risk. For what
regards the H. pylori infection, results from several large-
scale prospective randomized studies showed marginal
benefits of H. pylori eradication on regression of premalig-
nant gastric lesions while its importance is doubtful in the
reduction of GC incidence [33]. However, since H. pylori
eradication was demonstrated to prevent the recurrence of
peptic ulcer and gastric cancer (secondary prophylaxis) and
is the treatment of choice for patients with low grade gastric
MALToma [33], a substantial portion of GC-relatives could
benefit from its eradication.
MTHFRisakeyenzymeinthe metabolismoffolatewhich
providesmethyldonorforDNAsynthesisandgeneregulation
[22]. Several studies have found an association between
677TT status and several risk of cardiovascular diseases [1]
or cancers, as postmenopausal breast cancer [34], colorectal
cancer [23,35,36], and lung cancer [37]. Recently, the
association of 677TT and 1298CC polymorphisms and the
risk of GC have been re-evaluated in four meta-analyses
[16–19]. However, the effect of differential magnitude in
different geographical regions was significant. MTHFR
677TT genotype was found to be a strong risk factor in
Chinese and East Asian populations [16,17], a risk factor in
some, but not in all populations in Italy [15,16], Southern
Europe [18,38,39], and in South America population studies
[18,19]. It was found to be insignificant in other populations,
as in the Korean or the North American ones [16,18]. GC
association with 1298CC variant was limited to East Asian
[16], and in a study on Southern Europe [15], while it
resulted inconsistent in other studied populations [18,19].
According to the majority of reports [18,19,38], our data
support the association between 677TT genotype and GC in
Italy (OR 1.984 95% CI: 1.027 to 3.8329), and this is
Table 3 Allele frequencies of the MTHFR 667 and 1298 polymorphisms in controls, GC patients, and GC-first grade relatives
Numbers 667 allele frequency 1298 allele frequency
CT A C
Controls 454 390 (85.9%) 302 (66.5%) 413 (90.1%) 275 (60.6%)
Sex- and age-matched controls 96 83 (86.5%) 59 (61.5%) 87 (90.6%) 63 (65.6%)
Men 315 266 215 291 182
Women 139 124 87 122 93
<54 years 411 354 272 372 250
≥54 years 43 36 30 41 25
GC cases 57 43
a (75.4%) 39 (68.4%) 52 (91.2%) 32 (56.1%)
Sex- and age-matched GC 48 35 (72.9%) 36 (75.0%) 43 (89.6%) 24 (50.0%)
Men 35 27
b 25 31 22
Women 22 16
c 14 21 10
<54 years 29 22 21 26 13
≥54 years 28 21 18 26 19
GC-relatives cases 37 32 (86.5%) 23 (62.2%) 35 (94.6%) 28 (75.7%)
Men 21 19 13 20 18
d
Women 16 13 10 15 10
<54 years 29 25 17 27 22
≥54 years 8 7 6 8 6
aOR=0.50, 95% CI: 0.261 to 0.974, with respect to controls
bOR=0.41, 95% CI: 0.197 to 0.875, with respect to men controls
cOR=0.32, 95% CI: 0.109 to 0.950, with respect to women controls
dOR=4.385, 95% CI: 1.265 to 15.195, with respect to men controls
28 Tumor Biol. (2010) 31:23–32Table 4 Association between MTHFR genotype and gastric cancer risk stratified by sex and age
MTHFR 677 AA MTHFR 1298 AC CC
Cases
(n)
Controls
(n)
OR 95% CI Cases
(n)
Controls
(n)
OR 95% CI Cases
(n)
Controls
(n)
OR 95% CI
Overall GC cases
CC 3 24 1.0 – 11 90 1.0 (0.3–3.8) 4 38 0.8 (0.2–4.1)
CT 9 98 0.7 (0.2–2.9) 15 137 0.9 (0.2–3.3) 1 3 2.7 (0.2–34.5)
TT 13 57 1.8 (0.5–7.0) 1 7 1.1 (0.1–12.8) ––
Men
CC 2 19 1.0 – 5 58 0.8 (0.1–4.6) 3 23 1.2 (0.2–8.2)
CT 4 70 0.5 (0.1–3.2) 12 95 1.2 (0.2–5.8) 1 1 9.5 (0.4–217)
TT 7 44 1.5 (0.3–8.0) 1 5 1.9 (0.1-25.0) - -
Women
CC 1 5 1.0 – 6 32 0.9 (0.1–9.5) 1 15 0.3 (0.1–6.4)
CT 5 28 0.9 (0.1–9.3) 3 42 0.3 (0.1–4.1) – 2 0.7 (0.1–25)
TT 6 13 2.3 (0.2–24.0) 0 2 0.7 (0.1–25.0) ––
Overall at the age of
diagnosis/selection
<54 years
a
CC 3 21 1.0 – 2 82 0.2 (0.0–1.1) 2 36 0.4 (0.1–2.5)
CT 7 90 0.5 (0.1–2.3) 8 122 0.5 (0.1–1.9) 1 3 2.3 (0.2–30.4)
TT 5 50 0.7 (0.1–3.2) 1 7 1.0 (0.1–11.2) ––
Overall at the age of
diagnosis/selection
≥54 years
a
CC – 3 1.0 – 9 8 7.8 (0.3–174) 2 2 7.0 (0.2–219)
CT 2 8 2.1 (0.1–54.9) 7 15 3.4 (0.1–74) ––
TT 8 7 7.9 (0.4–180) –– ––
Men at the age of
diagnosis/selection
<54 years
CC 2 16 1.0 –– 54 0.1 (0.0–1.3) 1 21 0.4 (0.1–4.6)
CT 3 64 0.4 (0.1–2.4) 6 83 0.6 (0.1–3.1) – 1
TT 1 38 0.2 (0.1-2.5) - 5 0.6 (0.0-14) - -
Men at the age of
diagnosis/selection
≥54 years
CC - 3 1.0 – 5 4 8.5 (0.3–213) 2 2 7 (0.3–219)
CT 1 6 1.6 (0.1–51.1) 6 12 3.6 (0.2–81) 1 –
TT 6 6 7 (0.3–164 ) 1 –– –
Women at the age of
diagnosis/selection
<54 years
CC 1 5 1.0 – 2 28 0.4 (0.1-4.7) 1 15 0.3 (0.1-6.4)
CT 4 26 0.8 (0.1–8.4) 2 39 0.3 (0.1–3.3) – 2
TT 4 12 1.7 (0.2–18.9) – 2 ––
Women at the age of
diagnosis/selection
≥54 years
CC –– 44 ––
C T 12 13 ––
TT 2 1 –– ––
MTHFR 677TT/1298CC genotype was not observed in the study population
OR odds ratio, CI confidence interval
aWe used 54 years old as an arbitary criterio corresponding to the median age at diagnosis/selection of GC cases
Tumor Biol. (2010) 31:23–32 29confirmed when age–sex-matched GC and control groups
were compared (OR=2.3714; 95%CI: 0.9992 to 5.6283).
Any 1298CC genotype correlation was found in GC when
compared with controls (Tables 2 and 3). We found that
only the 677TT genotype increased the risk for GC, while
the single 677Tallele was statistically insignificant (Tables 2
and 3). This is in accordance with a recessive mode of
inheritance for a GC risk due to the mutation.
677TT and 1298CC frequencies in our control series
(13–14% and 9–14%) were similar to those found in other
studies in Europe (5–30% and 10%, respectively) [19,40]
and in Italy (14–19.9% and 7.5%) [41]. The crude 677TT
OR found, 1.98 and 2.37, was in accordance with that
found in the majority of Italian studies, 1.81 to 2.95
[18,19], but differed from Vollset study, 0.90 [15].
Nevertheless, the 677TT and 1298CC frequencies reported
(21.3% and 7.7%, respectively) were not dissimilar to ours
(13–14% and 9–14%) [15]. Nonetheless, although data of
MTHFR genotyping based on stratification by sex and age
did not reach statistical significance in our series (Table 4),
Table 5 Distribution of MTHFR genotypes in overall GC-relative cases and in GC-relative cases stratified by sex
MTHFR 677 AA MTHFR 1298 AC CC
Cases (n) Controls (n) OR 95% CI Cases (n) Controls (n) OR 95% CI Cases (n) Controls (n) OR 95% CI
GC-relatives
CC 1 24 1.0 – 11 90 0.2 (0.1–0.9) 2 38 0.4 (0.1–2.0)
CT 3 98 0.7 (0.1–7.4) 15 137 0.9 (0.4–2.0) – 3
TT 5 57 2.1 (0.2–18.9) – 7 ––
Men
CC 0 19 1.0 – 7 58 5.0 (0.3–91) 1 23 2.5 (0.1–65)
CT 1 70 0.8 (0.0–21) 10 95 4.3 (0.0–76) – 1
TT 2 44 2.2 (0.1–48) – 5
Women
CC 1 5 1.0 – 4 32 0.6 (0.1–6.2) 1 15 0.3 (0.2–6.4)
CT 2 28 0.4 (0.1–4.7) 5 42 0.5 (0.6–6.2) – 2
TT 3 13 1.1 (0.1–14) – 2 ––
MTHFR 677TT/1298CC genotype was not observed in the study population
OR odds ratio, CI confidence interval
667
genotype 
 667 
genotype/Hp pos 
1298
genotype 
 1298 
genotype/Hp pos 
CC  CT  TT  n CC  CT  TT  tot AA  AC  CC  n  AA  AC  CC  tot
GC 8      6     3  17  4      3      1  8    6       9      2  17  2      5      1  8 
GC-relatives   14    18     5  37    7    11      2  20    9     26      2  37    4    14      2     20 
Relative HP frequency distribution in 677
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Fig. 2 MTHFR polymorphisms
and H. pylori infection in GC
patients and in GC-first grade
relatives. a The table indicates
the number of persons (columns
2 and 4) with a confirmed
histological HP infection in
association with the 677 and
1298 genotypes. b The graphic
evidences the similar HP infec-
tion frequency in GC and in
GC-relatives series. No
preferential HP distribution was
found among the 677 genotypes
30 Tumor Biol. (2010) 31:23–32data are suggestive that the difference in MTHFR poly-
morphism association and GC risk may be partially
ascribed to sex and age of recruited cases. An association
of homozygous 677TT genotype in women group and the
decrease of wild-type 677 allele frequency in both the sex
(Tables 2 and 3) support this finding. The suggestion, as
evidenced in Table 4, that an association could exist
between the presence of both the MTHFR, 677, and 1298
variant genotypes, and a higher risk of GC in patients ≥54
at diagnosis/recruitment, and the possible 1298CC reduced
risk in women, as found also in other cancer [42], require
further studies on a large series to be definitely elucidate.
Thus, the reasons for discrepancy between our and other
authors’ data and those reported [15] remain unknown, but
the increased frequency of the 1298CC genotype in their GC
cases could exclude an increase of 677TT. In fact, although
the two 677TT and 1298CC polymorphic sites were in
linkage disequilibrium [43,44], the 677TT/1298CC genotype
was absent in our series, as well as in others [15], suggesting
that 677TT/1298CC genotype results in a severely adverse
phenotype. Moreover, the limited number of cases studied,
the geographical divergences (the study summarizes Italy,
Spain, and Greece cases [15]), and the unknown genetic–
environmental interactions could also be implicated.
Anyway, all studies concerning Italian patients attested
at least one MTHFR genotype with a known reduced folate
reductase activity (677TT or 1298CC), [28] associated with
GC.
Based on this finding, we analyzed the MTHFR poly-
morphisms in a series of GC-relatives individuals with the
aim to improve techniques in the identification of high-risk
subpopulations (i.e., genetic counseling).
Despite the restriction of the limited number of subjects
enrolled (n=37), our data evidenced an increase in MTHFR
677TT genotype only in ascertained GC cases, but not on
GC-relatives (13.5% vs controls 14.1%, Tables 2 and 3).
Also, the difference in 1298CC genotype frequencies among
the GC-relatives (5.7%), GC (8.8%) and controls (14.1%)
was statistically insignificant. Only an increase in 1298
heterozygosis was found in GC-relatives (70.3%) with
respect to GC (47.4%, OR=2.22, 95% CI: 1.072 to 4.605).
In conclusion, our data reinforce the role of 677TT in GC
development in the northeast ofItaly, but our results are not as
consistentastoleadtoasanitarybenefitforaMTHFRgenetic
consultation among GC-relatives. In addition, in our study,
prevalence of H. pylori infection in GC-relatives was similar
to that in GC and resulted with a distribution independent of
677 genotypes (Figs. 1 and 2). Thus, the identification of
677TT genotype that is colonized by H. pylori does not to
constitute a subset of subjects that may benefit more than
others from H. pylori eradication (since this treatment could
result in reduced GC risk).
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